Amesite Inc

Análisis de la acción Amesite Inc (AMST)

$0.515

-0.021 (-4.15%)Al cierre

Loading chart…
Máximo
0.537
Apertura
0.537
Precio medio ponderado por volumen
0.52
Volumen
24.47K
Capitalización
7.04M
Mínimo
0.515
Importe
12.79K
EV/EBITDA, TTM
0.00

Amesite Inc. is a technology company. The Company focused on building and commercializing AI-powered solutions for the healthcare sector. The Company specializes in the development and marketing of business-to-consumer (B2C) and business-to-business (B2B) artificial intelligence (AI)-driven solutions, including its higher ed platform that offers professional learning. The Company's platform utilizes infrastructure to deliver both Amesite Engage for higher education and NurseMagic for healthcare. NurseMagic is a mobile app for healthcare professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. NurseMagic is designed for use across various healthcare modalities, such as skilled nursing, assisted living, memory care, home health, and rehabilitation centers.

amesite.com

Análisis de IA of Amesite Inc (AMST)

Vender

Amesite Inc is not a good buy right now due to its extremely low Relative Strength Index (RSI) of 11.041, indicating it is oversold, and a staggering year-to-date change of -74.25%, reflecting significant declines in its stock price. The company's financials show consistent net losses, with the latest EPS reported at -0.14 and a forward P/E ratio of 0, suggesting no expected profitability in the near future. The main risk is the substantial decline in stock value, with a 52-week low of 0.52, which indicates a lack of investor confidence and potential for further losses.

Métricas de valoración

El PER previsto actual de Amesite Inc (AMST) es 0.00, frente a su media de 5 años de -2.94.

PER previsto

Valor razonable
Media 5A P/E
-2.94
P/E actual
0.00
Sobrevalorada
5.76
Infravalorada
-11.63

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
-3.91
EV/EBITDA actual
0.00
Sobrevalorada
17.01
Infravalorada
-24.83

Precio/ventas previsto

Valor razonable
Media 5A P/S
1.59
P/S actual
0.00
Sobrevalorada
4.22
Infravalorada
-1.04

Cronología de eventos

2026-09-24 (ET)

07:00:00

Amesite Launches New Sales Model, NurseMagic Enterprise Priced at $1,099 per Month

2026-05-12 (ET)

17:30:00

Amesite Files Prospectus for Resale of 4.84M Shares

2026-04-27 (ET)

12:40:00

Amesite Issues 696,866 Shares at $1.435 Each

11:20:00

X-energy and Yesway Show Strong Debut Performance

09:40:00

Amesite Files for Withdrawal of S-1 Registration Statement

Noticias

Preguntas frecuentes sobre AMST, respondidas por Alphio AI

Amesite Inc. is a technology company. The Company focused on building and commercializing AI-powered solutions for the healthcare sector. The Company specializes in the development and marketing of business-to-consumer (B2C) and business-to-business (B2B) artificial intelligence (AI)-driven solutions, including its higher ed platform that offers professional learning. The Company's platform utilizes infrastructure to deliver both Amesite Engage for higher education and NurseMagic for healthcare. NurseMagic is a mobile app for healthcare professionals, streamlines creation of nursing notes and documentation tasks, enhances patient communication, and offers personalized guidance to nurses on patient care, medications, and handling challenging workplace situations. NurseMagic is designed for use across various healthcare modalities, such as skilled nursing, assisted living, memory care, home health, and rehabilitation centers. It operates in the Technology sector (SERVICES-PREPACKAGED SOFTWARE industry).

Amesite Inc is not a good buy right now due to its extremely low Relative Strength Index (RSI) of 11.041, indicating it is oversold, and a staggering year-to-date change of -74.25%, reflecting significant declines in its stock price. The company's financials show consistent net losses, with the latest EPS reported at -0.14 and a forward P/E ratio of 0, suggesting no expected profitability in the near future. The main risk is the substantial decline in stock value, with a 52-week low of 0.52, which indicates a lack of investor confidence and potential for further losses.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar